Caliper Life Sciences (CALP)

2. Acquisitions

        On August 9, 2006, Caliper completed its acquisition of Xenogen Corporation for $62.1 million, consisting of $52.2 million in Caliper common stock, $7.1 million in warrants and $2.8 million of estimated direct acquisition costs. The final allocation of the purchase price was completed by August 9, 2007 and resulted in a $60,000 increase in goodwill. Xenogen's operations are included in the results of Caliper for all periods after August 9, 2006.

3. Acquisitions

On August 9, 2006, Caliper completed its acquisition of Xenogen Corporation for $62.1 million, including $52.2 million in Caliper common stock, $7.1 million in warrants and $2.8 million of estimated direct acquisition costs. The allocation of the purchase price will be completed prior to August 9, 2007 based upon the finalization of estimated assumed obligations and liabilities. Xenogen’s operations assumed as of the date of acquisition are included in the results of Caliper for all periods after August 9, 2006.

3. Acquisitions

On August 9, 2006, Caliper completed its acquisition of Xenogen Corporation for $62.1 million, including $52.2 million in Caliper common stock, $7.1 million in warrants and $2.8 million of estimated direct acquisition costs. The allocation of the purchase price is expected to be finalized within one year of the acquisition upon resolution of assumed obligations and potential liabilities. Xenogen’s operations assumed as of the date of acquisition are included in the results of Caliper for all periods after August 9, 2006.

7